Gamida Cell

Company Overview

Snapshot

Founded in February 1998, Gamida Cell operates with 51–200 employees and has raised over $416.22 million across 17 funding rounds from 15 investors. The company was acquired by Highbridge Capital Management in March 2024.

Business overview

Gamida Cell is a Health Tech & Life Sciences company pioneering cellular therapy through the use of nicotinamide (NAM) to expand various cell types, including stem cells and natural killer (NK) cells, while preserving their original characteristics and efficacy. Its core technology, applied to umbilical cord blood-derived cells, has led to the development of Omisirge (omidubicel-onlv), an allogeneic cell therapy approved by the FDA to reduce infection risk in blood cancer patients. The company also develops NAM-expanded NK cells for oncology applications, both in unmodified and genetically engineered forms. Gamida Cell serves the pharmaceutical and healthcare industries, focusing on treatments for cancer, hematology, and autoimmune diseases within the regenerative medicine and cell therapy sectors.

Strategic signal

In March 2024, Gamida Cell was acquired by Highbridge Capital Management. This acquisition signals a significant strategic shift for the company, moving from an independent publicly traded entity to being part of an investment firm's portfolio. For investors, this indicates a potential restructuring and new strategic direction under Highbridge Capital Management, aiming to stabilize and potentially re-leverage Gamida Cell's cellular therapy assets.

Company Intelligence Q&A

When was Gamida Cell acquired?

Gamida Cell was acquired by Highbridge Capital Management in March 2024.

What was a key product development for Gamida Cell in September 2023?

In September 2023, the first patient received Gamida Cell's Omisirge™ (omidubicel-onlv), an allogeneic cell therapy.

What financial results did Gamida Cell report in November 2023?

In November 2023, Gamida Cell reported its Third Quarter 2023 Financial Results and provided a company update.

What data did Gamida Cell present in November 2023 regarding its therapies?

In November 2023, Gamida Cell presented new data on its allogeneic stem cell therapy omidubicel and natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

What was a significant event for Gamida Cell in October 2018?

In October 2018, Gamida Cell completed an Initial Public Offering on NASDAQ, raising $50 million at a valuation of $210 million.